The patient can consult the possibility of cancer
chemoprevetion in the case of expose to high-risk
danger carcinoma
chemoprevetion in the case of expose to high-risk
danger carcinoma
The patient can consult the possibility of cancer
chemoprevention in the case of expose to high-risk danger
carcinoma. Chemoprevention of cancer is promising and hopeful
branch of oncology. There are several clinical trials, which
confirm usefulness of this new approach to oncological
medicine. Although we are at the very beginning on this field,
we can use some knowledge in the clinical practise..
Several examples:
The present randomised trial for prevention of women with
high risk of breast carcinoma between Tamoxifen and Raloxifen
(Evista) is not finished. Tamoxifen is in use for women with high
score of risk of breast carcinoma and is in clinical use.
Raloxifen is les carcinogen for uterus and is in use for treatment
of osteoporosis, but shows 78% lowering of breast carcinoma
for women using Raloxifen.
Sulindac sulphite and Sulindac sulphate is preventive agent
for colon carcinoma, especially for hereditary polyposis.
The patients with rheumatoid arthritis using antiflogistic agents
has lower incidence of colon cancer.
A clinical trial in Li-xian showed statistically significant influence
of some antioxidants and some trace elements for patients with
dysplastic changes. The field is too wide to describe all. The aim
is to normalize apoptosis during cancer development.
(Apoptosis is guided cell deaths. Proper healthy non-cancer cells
committed suicide due to central order - like in Socrates death!)
The same and laboratory results with genetically healthy
material achieved apoptosis normalisation.
For example:
melanoblastic malignant cells become melanocytic back again.
